The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.
Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. Due to the increase in research activities, both the availability of funding for research and the demand for and manufacturing of cell-based assay products are expected to grow.
The increased demand for research on COVID-19 has created a large scope for cell-based 45 assays in viral infection research, vaccine development, and overall drug discovery for both researchers and laboratories.
Currently, a number of vaccines or antiviral drugs for COVID-19 have been approved or are under development, and patients are currently treated symptomatically. For both vaccines and therapeutics, the antibodies produced are tested for their functional efficacy to neutralize the target virus.
Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
Cell-based assays are employed to shorten the time and increase the throughput needed for these assays. This has significantly increased the demand for cell-based assays to provide an early indication of the toxicity characteristics of the drug candidates.
It is also not possible to prepare or purify every target for biochemical measurement, which is a major factor limiting the applications of biochemical assays. As a result, pharmaceutical & biotechnology companies as well as CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery.
The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell-based assays has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments.
According to estimates from the World Bank, the R&D spending in emerging economies in Asia and RoW has surpassed that of North America and Europe. Additionally, the increasing number of pharmaceutical companies and CROs—key end-users of cell-based assays—in these countries is expected to offer potential growth opportunities for manufacturers of cell-based assays.